Intrathecal morphine was first described for obstetric analgesia in the early 1980s1 and has since become widely used for analgesia after cesarean delivery because of its prolonged postoperative analgesic effects.2,3 However, intrathecal morphine can result in side effects such as nausea, vomiting, pruritus, sedation, and respiratory depression.4 The quality of analgesia and incidence of side effects may vary according to the dose of intrathecal morphine used.2 An online survey of Society of Obstetric Anesthesia and Perinatology members demonstrated that the majority (87%) of anesthesiologists use between 50 and 250 μg morphine, with 200 μg being the most commonly (38%) prescribed dose.5 The trade-off between analgesic efficacy and incidence of side effects when using 100 and 200 μg morphine is a clinical dilemma, which has been previously highlighted.6 The ideal dose capable of providing optimal postoperative analgesia for cesarean delivery with the lowest incidence of side effects has not yet been determined. Although dose-response relationships have been described after epidural morphine administration,7,8 conflicting evidence surrounds the dose relationship of intrathecal morphine and analgesic efficacy.3,9,10
The aim of this meta-analysis was to determine whether low- or high-dose intrathecal morphine provides acceptable duration and intensity of analgesia with fewer side effects. We also sought to elucidate whether morphine doses used in modern obstetric anesthetic practice demonstrated a dose-response relationship for analgesia and side effects. Specifically, we compared the time from intrathecal morphine administration until first request for supplemental analgesia (as a surrogate for duration of analgesia), in patients receiving low doses (LD; 50–100 μg) of intrathecal morphine, to those who received higher doses (HD; >100–250 μg). Secondary outcomes included maternal pain scores, morphine usage, side effects (nausea, vomiting, pruritus, and respiratory depression), and neonatal outcomes (umbilical arterial and venous pH and Apgar scores at 1 and 5 minutes).
For this meta-analysis, we sought randomized controlled trials (RCTs) in women who were not in labor undergoing elective or scheduled cesarean delivery under spinal anesthesia comparing LD (between 50 and 100 μg) to HD (>100 to 250 μg) intrathecal morphine. We conducted a literature search with no language restriction on April 29, 2014, and repeated the search on September 9, 2014. Searches were performed in PubMed (1950 to April 2014), Ovid EMBASE (1970 to April 2014), Ovid MEDLINE (1950 to April 2014), Scopus (1960 to April 2014), EBM Reviews Cochrane Central Register of Controlled Trials 2nd Quarter 2014, CINAHL (April 2014), and Web of Science (September 2015). We attempted to reduce publication bias by consulting the clinical trials registry (www.clinicaltrials.gov) on April 29, 2014. The search strategy consisted of a combination of subject headings (obstetric, cesarean, and caesarean) and keywords/key phrases (morphine and cesarean) for each of MEDLINE, EMBASE, and CINAHL, searched in specified fields (such as ti = title/ab = abstract). In the event that a database did not index articles, we conducted keyword searching in the entire record (Supplemental Digital Content 1 for detailed PubMed search criteria; other search strategies are available from the authors, http://links.lww.com/AA/B393). Reference lists of all identified studies as well as those of previous meta-analyses on similar topics were checked.
All RCTs using intrathecal morphine for cesarean delivery were considered. We only included studies comparing groups that administered ≥50 μg and ≤250 μg for elective or scheduled cesarean delivery. We excluded studies that combined different opioids (e.g., sufentanil or fentanyl) with morphine (e.g., morphine 100 μg + fentanyl 25 μg versus morphine 200 μg + fentanyl 5 μg). Studies were also excluded if they did not evaluate maternal or neonatal outcomes. The quality of studies included in the meta-analysis was reviewed by using the Cochrane Collaboration’s tool for assessing the risk of bias.11 Areas of methodologic quality assessed included concealment of allocation, random sequence generation, blinding of the assessors and participants, and accounting for all subjects. Overall quality of reporting was graded using the 5-point Jadad scale.12 At least 2 individuals extracted the study data independently using a standardized review protocol and recorded the information on a data collection sheet. Differences were resolved by reexamination of the original articles and by discussion with a third reviewer. The data were entered into a computer by 1 of the authors and checked by 2 investigators. Publication bias was assessed using the Egger test.13
The primary outcome was the duration of analgesia, defined by the authors of the meta-analysis as the time from intrathecal morphine administration until the patient’s first request for analgesia. Secondary outcomes included other measures of analgesia (pain scores and morphine use), maternal side effects (nausea, vomiting, pruritus, and respiratory depression), and neonatal outcomes (umbilical arterial and venous pH and Apgar scores at 1 and 5 minutes).
Pain scores (evaluated at 12 and 24 hours) were converted to a unitless 0 to 100 scale, where 0 represents no pain and 100 represents worst pain imaginable to enable comparison among studies. Supplemental morphine consumption (up to 24 hours) was compared by converting opioids used postoperatively to an equivalent dose of IV morphine.14 Twenty-four-hour incidences of nausea (as defined by individual studies), vomiting and pruritus (as defined by each individual study), and severe pruritus were compared between groups. We also compared the need for antiemetic agents. Patients who required antipruritic agents were considered to have experienced severe pruritus. Maternal respiratory depression was defined as incidence of respiratory rate (RR) <10 per minute within 24 hours of intrathecal morphine administration.
When possible, data were combined and analyzed using Review Manager 5.3 (Review Manager [RevMan] Version 5.3; The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark, 2011). For dichotomous outcomes, the odds ratio (OR) and 95% confidence interval (CI) were calculated. In addition, risk difference and number needed to harm were calculated for dichotomous side effects. For continuous data, the mean difference (MD) and 95% CI were determined. The percentage of heterogeneity was assessed with the I2 statistic. Publication bias was assessed using Egger regression test and illustrated by a funnel plot. A P value <0.05 was considered statistically significant. All data were combined and analyzed using the DerSimonian-Laird random effects model.15 Qualitative assessment was performed for variables that had no occurrences within study groups.
A flow diagram outlining study selection is provided in Figure 1. Two publications were identified from reference lists of retrieved articles but neither met inclusion criteria for this meta-analysis. Excluded studies are listed in Supplemental Digital Content 2 (http://links.lww.com/AA/B393).6,16–37 We retrieved all 34 shortlisted articles that were identified from the literature search. Eleven articles met our inclusion criteria.3,9,10,38–45 Four hundred eighty patients were recruited in all study groups (247 in the LD group and 233 patients in the HD group). The included studies are summarized in Table 1, methodology pain assessment and outcomes are summarized in Table 2, and methodology of secondary outcomes is summarized in Table 3. The funnel plot for the primary outcome is shown in Figure 2. There was no evidence of publication bias, as shown by the Egger test, P value = 0.91. The risk-of-bias assessment is shown in Figure 3.
Time to First Analgesic Request
Of the 11 included studies, 7 reported data on the primary outcome. These 7 studies included 294 subjects in total (Fig. 4; 168 patients in LD group and 126 in the HD group). The MD for time to first request for additional analgesia was 4.49 hours, which is higher in the HD group (95% CI, 1.85–7.13 hours; P = 0.0008; Fig. 4). The range of mean times to first analgesic request in the HD group was between 13.8 and 39.5 hours compared with 9.7 to 26.6 hours in the LD group. Moderate heterogeneity was observed for this outcome (I2 = 50%). Because an inadequate description of blinding to allocation was the most serious source of bias, we performed a sensitivity analysis comparing studies blinded to allocation to those that were not. There were 4 studies in which there was no concealment of allocation9,39,41,42 and 3 studies in which the allocation was appropriate or unclear.10,40,44 In both of these groups, there was significant prolongation of analgesia in the HD group compared with LD (MD = 5.9 hours; 95% CI, 0.18–11.54; P = 0.04 for unconcealed and MD = 4.4 hours; 95% CI, 1.8–7.1 hours; P = 0.0009 for the concealed studies). In this sensitivity analysis, the MD between allocation groups was not statistically different (P = 0.66).
Pain Scores and Morphine Consumption
There were no differences in pain scores (converted to 0–100 if possible; if not possible, data were not included in the analysis) at 12 and 24 hours after delivery between groups (Table 4). Pain was measured in most studies using a visual analog scale (0–10-cm10,38–40,42,45). Other scales used among the studies included 0 to 5 differential verbal pain score rating41 and a 0 to 21 cumulative scoring system.3 Morphine consumption at 24 hours was similar between groups (Fig. 5).
Maternal Side Effects
The 24-hour incidences of maternal nausea or vomiting, vomiting, need for antiemetics, pruritus, and severe pruritus are outlined in Table 4. The incidence of pruritus was greater in the HD group (Fig. 6). The number needed to harm for pruritus and severe pruritus was 5.9 (95% CI, 3.4–20.0; P = 0.007), 7.0 (95% CI, 4.0–50.0; P = 0.02), respectively.
Sensitivity analysis for pruritus was also performed using 4 studies in which there was no allocation concealment9,41–43 and 4 studies in which the allocation concealment was appropriate or unclear.10,38,40,44 In both of these groups, there was a significantly higher incidence of pruritus in the HD group compared with LD group (OR = 0.14; 95% CI, 0.04–0.44; P = 0.0008 for nonconcealed allocation and OR = 0.44; 95% CI, 0.24–0.81; P = 0.009 for the concealed studies). In this sensitivity analysis, the ORs were not statistically different (0.14 vs 0.44; P = 0.08).
Sensitivity analysis for nausea and vomiting was also performed using 3 studies in which there was no allocation concealment9,39,42 and 4 in which the allocation concealment was appropriate or unclear.38,40,44,45 The incidence of nausea and vomiting was higher in the HD group compared with the LD group in both allocation groups (OR = 0.61; 95% CI, 0.32–1.14; P = 0.12 for concealed studies and OR = 0.26; 95% CI, 0.12–0.60; P = 0.001 for the nonconcealed studies). The ORs were not different between concealed and nonconcealed studies (0.61 vs 0.26; P = 0.12).
Eight studies investigated the incidence of maternal respiratory depression in the 24 hours after intrathecal morphine administration. Three studies defined respiratory depression as RR <10/min,38,39,41 1 study as RR <8/min,9 and 1 study as RR <10/min or oxygen saturation (Spo2) <93%,10 and 3 studies did not provide parameters for their definition of respiratory depression.40,42,44 None of the studies reported any patients experiencing respiratory depression in any of the morphine groups. One study explored the difference between LD and HD morphine groups on respiratory depression by using the ventilatory responses to progressive hypercapnia using a modified Read rebreathing technique (involving extrapolating carbon dioxide response curves with a computer-controlled data acquisition system).39 Ventilatory responses to carbon dioxide 2.5 to 3 hours after injection of morphine were not different from those in the placebo group, indicating that intrathecal morphine did not cause depression of the ventilatory variables in this time frame.
Three studies investigated neonatal outcome at delivery. All 3 reported data on neonatal Apgar scores at 1 and 5 minutes, with 1 study also reporting additional data on umbilical cord blood gases. The incidence of Apgar scores <7 at 1 minute was not significantly different between groups (OR, 1.11; 95% CI, 0.06–20.49; P = 0.94). There were no incidences of Apgar scores <7 at 5 minutes in any of the 3 studies that assessed this outcome. The one study investigating umbilical cord blood gases reported no neonates with umbilical artery pH of <7.2 with the administration of either 0.1 or 0.25 mg intrathecal morphine.39
The primary finding of this study is that the mean time to requirement of supplemental analgesia with HD (>100–250 μg) intrathecal morphine is approximately 4.5 hours longer than with LD (50–100 μg). Although this is the best estimate of treatment effect, the CI around this value warrants discussion. Based on the calculated 95% CI, the duration of analgesia is prolonged by between 1.9 and 7.1 hours. This interval may be too conservative because of the small number of studies, heterogeneity among studies, and the possibility that the data in each study are not normally distributed. The more conservative 99% CI yields an increase in duration of analgesia between 1.0 and 8.2 hours for HD compared with LD intrathecal morphine. Factors that may have been responsible for the heterogeneity include the use of different protocols for the administration of adjuvant analgesic agents and other factors that may cause variations among study participants (e.g., geography, ethnicity).
Use of multimodal analgesic therapy has been shown to improve analgesia and decrease opioid requirements after cesarean delivery.46 The studies in this meta-analysis used a variety of nonsteroidal antiinflammatory drugs (NSAIDs) (indomethacin, ketoprofen, diclofenac, and naproxen) administered via different routes and in various regimens including intraoperative use only,43 perioperative and regular postoperative use,38,42,45 regular postoperative use only,44 and as required postoperative use.10 Furthermore, various different definitions were used among the studies for duration of analgesia, including time until pain score reached a certain level (>2/541 or visual analog scale pain score <50/10039), time to first meperidine request,40 time to first analgesic request,9,42,44,45 and time to first patient-controlled analgesia dose administration.10 Pain score assessment in many of the studies also did not state the site of pain scores or whether taken at rest or on movement.
Dahl et al.2 in 1999 observed a prolonged time to first postoperative analgesia with the use of intrathecal morphine compared with placebo/control; however, they did not analyze a dose response. Their reported median time to first analgesic requirement after cesarean delivery was 27 hours (range, 11–29) with various doses of intrathecal morphine (50–200 μg) with or without other intrathecal opioids (sufentanil, fentanyl, and buprenorphine). Our results demonstrate that duration of analgesia after cesarean delivery is dependent on the intrathecal dose of morphine. A systematic review of various epidural morphine doses after cesarean delivery reported median time until first request for analgesia as 19.0 hours (range, 5.4–29.2 hours); and duration of analgesia was longer with larger epidural morphine doses (8.9 hours with 2 mg vs 26.8 hours with 6 mg).8 However, the largest RCT to date exploring the effect of epidural morphine on analgesic duration demonstrated no significant difference between 1.5 and 3 mg.7 This study by Singh et al.7 included a multimodal regimen with scheduled NSAIDs for both arms of the trial. This result suggests that multimodal analgesic regimens may mitigate analgesic differences between LDs and HDs of intrathecal morphine. Multimodal analgesia was used in 6 studies (4 studies using NSAIDs9,10,38,44 and 2 studies using NSAIDs and acetaminophen).42,45
Of the 11 studies in our review, 9 studies considered 100 μg morphine as LD.9,10,38–40,42–45 Three of the studies included in this meta-analysis had >1 group in the LD group.3,9,41 These groups were combined and compared with the HD group. Only 1 of these studies reported duration of analgesia.41 In this study, the authors showed a significant dose response over the range of doses (0–125 μg) although the dose response for side effects such as pruritus and vomiting was not apparent. Palmer et al.3 studied a wider range of doses (100–500 μg) but did not report the duration of action. They noted an increase in IV patient-controlled morphine use in women who received lower doses but concluded this was not a linear relationship. Unfortunately, there are not enough patients in our studies to conduct a meta-regression based on individual doses. Nor would a sensitivity analysis based on dose produce significant results when examining the primary outcome or side effects because of lack of power.
Neuraxial compared with parenteral opioids have been found to consistently decrease pain and opioid requirement after cesarean delivery.2 With the increase in analgesic duration demonstrated with HD morphine, we expected differences in pain scores and morphine consumption between groups. However, we found no differences in pain scores at 12 and 24 hours or morphine consumption at 24 hours between the HD and LD intrathecal morphine groups. Based on a longer duration of action with HDs of intrathecal morphine, we would expect greater differences in analgesic effects over the 24- to 48-hour period after surgery. Pain scores and morphine usage were, however, only consistently recorded until 24 hours within the included studies, and therefore, greater breakthrough pain and analgesia doses beyond this period of time may have been missed through the design of studies.
The results of studies exploring intrathecal morphine doses and pain or analgesic use after cesarean delivery are inconsistent.3,9,10,42,45 For assessment of analgesic efficacy, the isolated statistical analysis of pain score or morphine consumption as surrogate markers for pain not only loses statistical efficiency but may also incur increased false-positive findings because of multiple testing.47 It is possible that some women used an increased amount of opioids to reduce pain to acceptable levels, and others may have tolerated higher pain scores to avoid opioids and their related side effects. Tools are available to measure this interaction47; however, integrated outcomes evaluating this were not possible in this study because we did not have access to individual patient data. Other possible explanations for the disparity demonstrated among studies include regional differences in pain scales and opioid use, small sample size,6 postpartum maternal avoidance of opioids despite presence of pain to minimize breastfeeding-related neonatal drug exposure,48 and the standard 24-hour study assessment methodology used in many studies is likely to miss the peak in postoperative pain that occurs 36 to 48 hours after neuraxial morphine administration for cesarean delivery.49
Although the association between the use of neuraxial morphine and increased maternal side effects (pruritus, nausea, and vomiting) is well described,4,8 the dose-response relationship is less consistently shown in studies. This meta-analysis demonstrates significant differences in pruritus between the HD and LD intrathecal morphine groups. Significant differences were also demonstrated after sensitivity analyses for both studies with and without adequate concealment of allocation group for the outcomes of duration of analgesia and pruritus. Our results are consistent with the findings from Dahl et al.2 and Palmer et al.,3 who describe increased pruritus with higher intrathecal morphine doses. Palmer et al. found no differences in nausea or vomiting with increasing dose of intrathecal morphine (25–500 μg).3 In contrast, our meta-analysis did find an increase in nausea or vomiting. Increased nausea or vomiting is consistent with previously reported increased antiemetic use (52% vs 24%) with 200 μg compared with 100 μg intrathecal morphine for cesarean delivery.6 This meta-analysis confirms that larger intrathecal morphine doses are associated with increased maternal opioid-related pruritus and nausea or vomiting, which should be considered when selecting the optimal dose of intrathecal morphine. The “better studies” did not show the statistical difference, probably because there were too few studies, but the possibility of bias in the “poorer studies” cannot be excluded. Sensitivity analysis for the outcome of nausea and vomiting did not demonstrate statistical significance in the studies with adequate concealment, which may have been attributable to the presence of too few studies for this analysis. Furthermore, the possibility of bias in the studies without concealment cannot be excluded.
Neonatal outcomes were not significantly different between groups. It should, however, be noted that none of the studies included in this meta-analysis were powered to demonstrate differences in the neonatal outcomes assessed. Similarly, none of the studies had sufficient power to detect maternal respiratory depression.
This analysis shows that duration of analgesia of intrathecal morphine can be prolonged by increasing the dose, at the potential expense of increasing maternal side effects. This information can be used to help decide the correct choice of intrathecal morphine dose for women undergoing cesarean delivery. In particular, patients who are at high risk for severe postoperative pain may benefit from an increased dose of intrathecal morphine, and women reporting sensitivity to opioids and their related side effects may benefit from lower doses.50
There are several limitations to this study. Studies included in the analysis for the primary outcome of time until first request for analgesia may be at risk of selection bias because concealment of allocation was not described. Sensitivity analysis considering allocation concealment to address the study quality did not, however, change the overall result for the primary outcome. Whether time to first request for supplemental analgesia correlates well with duration of analgesia was not evaluated in this study. Also, the variety of NSAID administration methods and varied use among studies may be a confounding factor in this analysis. Multimodal analgesic regimens may mitigate analgesic differences between LDs and HDs of intrathecal morphine. LD morphine may, for example, provide acceptable analgesia if combined with NSAIDs and/or acetaminophen but inadequate analgesia without NSAIDs and/or acetaminophen. This may also alter the duration of analgesia (i.e., small difference with NSAIDs and larger difference without NSAIDs). There was significant clinical heterogeneity in the local anesthetic drug dose and baricity across studies. In addition, the intraoperative and postoperative rescue analgesic drugs and the mode of analgesic administration varied among studies, resulting in heterogeneity for the primary outcome. The method of primary outcome measurement also varied among studies (Table 1). This meta-analysis included 5 studies from Asia, 4 from North America, 4 from Europe, and 1 from South America. The wide geographical study population may have increased heterogeneity; however, this geographic variation does increase generalizability of the results and could also be considered a strength of this study. We included studies using ≥50 μg morphine dose because smaller intrathecal morphine doses are rarely used or studied and may have limited efficacy.3 We used 100 μg as the cutoff for HD and LD to reflect common clinical practice5 and to be consistent with most studies that defined 100 μg as an LD intrathecal morphine. We excluded studies that used doses of intrathecal morphine >250 μg because these doses are not commonly used in clinical practice and may be associated with respiratory depression.4
We did not evaluate the probability distribution of the duration of pain relief; therefore, the lower 99% confidence limit of 1.0 hours should be considered as the amount of extra duration of analgesia at minimum achieved with the higher intrathecal morphine dose. We calculated the 95% CI for the ORs and weighted MDs; however, we acknowledge that the use of 99% confidence limits provides more robust coverage.51 Although this meta-analysis focused on pain, analgesic, and side effect outcomes, we appreciate that good measures for evaluating patient satisfaction are lacking. The optimal balance between analgesia and side effects may be best reflected by a global satisfaction measure. Dose selection should preferably account for patients’ preferences for pain relief and maternal desire to limit potential side effects. Further studies are needed to elucidate optimal dose selection that leads to greatest patient satisfaction.
In summary, this meta-analysis demonstrates that HDs of intrathecal morphine prolong analgesia after cesarean delivery. The additional MD of 4.5 hours of pain relief (may be as low as additional 1.0 hours and as much as 8.2 hours) must be balanced against the increased risk of maternal pruritus and nausea or vomiting. The trade-off between improved analgesia and increased side effects should be appreciated by both care providers and women undergoing cesarean delivery. Results from this study can be used by clinicians to aid decision making regarding drug selection and to inform patients of the benefits and potential side effects of using larger doses of intrathecal morphine for cesarean delivery.
Name: Pervez Sultan, MBChB, FRCA.
Contribution: This author helped design the study, conduct the study, and write the manuscript.
Attestation: Pervez Sultan has seen the original study data, reviewed the analysis of the data, approved the final manuscript, and is the author responsible for archiving the study files.
Name: Stephen H. Halpern, MD.
Contribution: This author helped design the study, conduct the study, analyze the data, and write the manuscript.
Attestation: Stephen Halpern has seen the original study data, reviewed the analysis of the data, approved the final manuscript, and is the author responsible for archiving the study files.
Name: Ellile Pushpanathan, MBBS, BMedSci, FRCA.
Contribution: This author helped design the study, analyze the data, and write the manuscript.
Attestation: Ellile Pushpanathan has seen the original study data, reviewed the analysis of the data, approved the final manuscript, and is the author responsible for archiving the study files.
Name: Selina Patel, MBBS, FRCA
Contribution: This author helped design the study, analyze the data, and write the manuscript.
Attestation: Selina Patel has seen the original study data, reviewed the analysis of the data, approved the final manuscript, and is the author responsible for archiving the study files.
Name: Brendan Carvalho, MBBCh, FRCA.
Contribution: This author helped design the study, conduct the study, and write the manuscript.
Attestation: Brendan Carvalho has seen the original study data, reviewed the analysis of the data, approved the final manuscript, and is the author responsible for archiving the study files.
This manuscript was handled by: Cynthia A. Wong, MD.
1. Baraka A, Noueihid R, Hajj SIntrathecal injection of morphine for obstetric analgesia.Anesthesiology19815413640
2. Dahl JB, Jeppesen IS, Jørgensen H, Wetterslev J, Møiniche SIntraoperative and postoperative analgesic efficacy and adverse effects of intrathecal opioids in patients undergoing cesarean section with spinal anesthesia: a qualitative and quantitative systematic review of randomized controlled trials.Anesthesiology199991191927
3. Palmer CM, Emerson S, Volgoropolous D, Alves DDose-response relationship of intrathecal morphine for postcesarean analgesia.Anesthesiology19999043744
4. Sultan P, Gutierrez MC, Carvalho BNeuraxial morphine and respiratory depression: finding the right balance.Drugs201171180719
5. Aiono-Le Tagaloa L, Butwick AJ, Carvalho BA survey of perioperative and postoperative anesthetic practices for cesarean delivery.Anesthesiol Res Pract20092009510642
6. Wong JY, Carvalho B, Riley ETIntrathecal morphine 100 and 200 μg for post-cesarean delivery analgesia: a trade-off between analgesic efficacy and side effects.Int J Obstet Anesth2013223641
7. Singh SI, Rehou S, Marmai KL, Jones PMThe efficacy of 2 doses of epidural morphine for postcesarean delivery analgesia: a randomized noninferiority trial.Anesth Analg201311767785
8. Bonnet MP, Mignon A, Mazoit JX, Ozier Y, Marret EAnalgesic efficacy and adverse effects of epidural morphine compared to parenteral opioids after elective caesarean section: a systematic review.Eur J Pain201014894.e19
9. Uchiyama A, Nakano S, Ueyama H, Nishimura M, Tashiro CLow dose intrathecal morphine and pain relief following caesarean section.Int J Obstet Anesth199438791
10. Girgin NK, Gurbet A, Turker G, Aksu H, Gulhan NIntrathecal morphine in anesthesia for cesarean delivery: dose-response relationship for combinations of low-dose intrathecal morphine and spinal bupivacaine.J Clin Anesth2008201805
11. Higgins JPT, Altman DGChapter 8: Assessing Risk of Bias in Included Studies2008LondonJohn Wiley & Sons Ltd
12. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJAssessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials199617112
13. Egger M, Davey Smith G, Schneider M, Minder CBias in meta-analysis detected by a simple, graphical test.BMJ199731562934
14. Hardman JG, Limbird LEGutstein HB, Akil HOpioid analgesics.Goodman and Gilman: The pharmacological Basis of Therapeutics2001New York, NYMcGraw-Hill569611
15. DerSimonian R, Laird NMeta-analysis in clinical trials.Control Clin Trials1986717788
16. Bassell GMAnesthesia for cesarean section.Clin Obstet Gynecol19852872234
17. Khapii K, Tiazhelkov VPPeridural analgesia using narcotic analgesics.Anesteziol Reanimatol19856670
18. Kadieva VS, van Hasselt CHLow dose intrathecal morphine for caesarean section.Anaesthesia198338122930
19. Kwan ASpinal morphine for caesarean section.Anaesth Intensive Care199725726
20. Nepo Karangwa J, Vial F, Uwambazimana J, Guerci P, Ndoli J, Raft J, Bouaziz HPostoperative pain management after caesarean section in Kigali University Medical Center: first use of intrathecal morphine.Ann Fr Anesth Reanim2013326312
21. Taylor R, Stedmon J, Barker LSpinal morphine for caesarean section.Anaesth Intensive Care199725198
22. Finucane BTSpinal anesthesia for cesarean delivery. The dosage dilemma.Reg Anesth199520879
23. Buggy DIntrathecal morphine dose for caesarean section.Anaesthesia199752278
24. Cardoso MM, Carvalho JC, Tahamtani SMIntramuscular versus rectal diclofenac associated with low dose spinal morphine for post-cesarean analgesia.Rev Bras Anestesiol20025266672
25. Carvalho FA, Tenório SBComparative study between doses of intrathecal morphine for analgesia after caesarean.Braz J Anesthesiol2013634929
26. Ganem EM, Módolo NS, Ferrari F, Cordon FC, Koguti ES, Castiglia YMEffects of low spinal morphine doses associated to intravenous and oral ketoprofen in patients submitted to cesarean sections.Rev Bras Anestesiol2003534319
27. Mikuni I, Hirai H, Toyama Y, Takahata O, Iwasaki HEfficacy of intrathecal morphine with epidural ropivacaine infusion for postcesarean analgesia.J Clin Anesth20102226873
28. Weigl W, Bieryło A, Krzemień-Wiczyńska S, Mayzner-Zawadzka EComparative study of postoperative analgesia after intrathecal administration of bupivacaine with fentanyl or morphine for elective Caesarean section.Anestezjol Intens Ter2009412832
29. Gerancher JC, Floyd H, Eisenach JDetermination of an effective dose of intrathecal morphine for pain relief after cesarean delivery.Anesth Analg19998834651
30. Krasznai PAnalgesia after cesarean section by peridural administration of morphine (preliminary report).Orv Hetil19811223212
31. Chinachoti T, Nilrat P, Samarnpiboonphol PNausea, vomiting and pruritus induced by intrathecal morphine.J Med Assoc Thai20139658994
32. DiBlasi SMPlanned cesarean delivery and urinary retention associated with spinal morphine.J Perianesth Nurs20132812836
33. Karaman S, Günüsen I, Uyar M, Biricik E, Firat VThe effects of morphine and fentanyl alone or in combination added to intrathecal bupivacaine in spinal anesthesia for cesarean section.Agri2011235763
34. Rivero JJ, Mojica MJB, Bello AHPDosis bajas de bupivacaina subaracnoidea reducen la incidencia de hipotensión durante la cesárea?Rev Colomb Anestesiol2004321717
35. Meléndez H, Gamarra HG, Fernández C, Dulcey REficacia del fentanyl adicionado a bupivacaina en el dolor intraoperatorio en cesárea bajo anestesia subaracnoidea: Ensayo clínico controlado.Rev Colomb Anestesiol2005331618
36. Nakamura T, Hase K, Fujihara T, Ogawa T, Urabe A, Asari E, Yoshioka HCombined intrathecal morphine and bupivacaine for elective post-caesarean pain.Masui20095841621
37. Hong JY, Lee IHComparison of the effects of intrathecal morphine and pethidine on shivering after Caesarean delivery under combined-spinal epidural anaesthesia.Anaesthesia200560116872
38. Sarvela J, Halonen P, Soikkeli A, Korttila KA double-blinded, randomized comparison of intrathecal and epidural morphine for elective cesarean delivery.Anesth Analg20029543640
39. Abboud TK, Dror A, Mosaad P, Zhu J, Mantilla M, Swart F, Gangolly J, Silao P, Makar A, Moore JMini-dose intrathecal morphine for the relief of post-cesarean section pain: safety, efficacy, and ventilatory responses to carbon dioxide.Anesth Analg19886713743
40. Cohen SE, Desai JB, Ratner EF, Riley ET, Halpern JKetorolac and spinal morphine for postcesarean analgesia.Int J Obstet Anesth19965148
41. Jiang CJ, Liu CC, Wu TJ, Sun WZ, Lin SY, Huang FY, Chao CCMini-dose intrathecal morphine for post-cesarean section analgesia.Ma Zui Xue Za Zhi1991296839
42. Milner AR, Bogod DG, Harwood RJIntrathecal administration of morphine for elective Caesarean section. A comparison between 0.1 mg and 0.2 mg.Anaesthesia1996518713
43. Sharma NR, Timalsena P, S DCIntrathecal morphine in combination with bupivacaine: a comparative study following caesarean section.Nepal Med Coll J201315379
44. Unlugenc H, Gunduz M, Guzel B, Isik GA comparative study on the effects of intrathecal morphine added to levobupivacaine for spinal anesthesia.J Opioid Manag2012810513
45. Yang T, Breen TW, Archer D, Fick GComparison of 0.25 mg and 0.1 mg intrathecal morphine for analgesia after Cesarean section.Can J Anaesth19994685660
46. Lavoie A, Toledo PMultimodal postcesarean delivery analgesia.Clin Perinatol20134044355
47. Dai F, Silverman DG, Chelly JE, Li J, Belfer I, Qin LIntegration of pain score and morphine consumption in analgesic clinical studies.J Pain20131476777.e8
48. Carvalho B, Cohen SE, Lipman SS, Fuller A, Mathusamy AD, Macario APatient preferences for anesthesia outcomes associated with cesarean delivery.Anesth Analg200510111827
49. Angle PJ, Halpern SH, Leighton BL, Szalai JP, Gnanendran K, Kronberg JEA randomized controlled trial examining the effect of naproxen on analgesia during the second day after cesarean delivery.Anesth Analg2002957415
50. Booth JL, Harris LC, Eisenach JC, Pan PHA randomized controlled trial comparing two multimodal analgesic techniques in patients predicted to have severe pain after cesarean delivery.Anesth Analg201612211149
51. Dexter F, Bayman EO, Epstein RHStatistical modeling of average and variability of time to extubation for meta-analysis comparing desflurane to sevoflurane.Anesth Analg201011057080